Liver Cancer | Tumor

Opdivo Regimen Pulled for Liver Cancer Treatment

July 28th 2021, 11:00pm

Article

Opdivo was granted an accelerated approval for patients with hepatocellular carcinoma, but the indication was pulled after follow-up data failed to show that the agent improved survival over another drug.

Researchers Discover a Culprit Behind Aggressive Liver Cancer

July 12th 2021, 3:00pm

Article

Patients whose disease contained the osteopontin protein tended to have more aggressive liver cancer that did not respond to treatment.

COVID-19 Pandemic Had Significant Impact on Liver Cancer Screenings and Care

July 9th 2021, 9:00pm

Article

Screening and diagnostic procedures for liver cancer as well as transplant programs and curative/palliative treatments were modified or delayed due to the COVID-19 pandemic, a new survey says.

Alcohol-Cancer Link Needs More Recognition

July 8th 2021, 1:00pm

Article

Most people surveyed knew about the link between alcohol and liver cancer, but far fewer knew that drinking could increase breast cancer risk, too.

Two-Drug Combo Shows Modest Benefit in Biliary Tract Cancer

June 15th 2021, 9:00pm

Article

Treatment with the combination of Stivarga and Bavencio was associated with minor anti-tumor activity in patients with advanced, heavily pretreated biliary tract solid tumors.

Onivyde Combo Improves Outcomes for Patients with Metastatic Liver Cancer

June 8th 2021, 8:00pm

Article

Onivyde combined with a chemotherapy agent and a chemotherapy-protective drug should be used as a second-line treatment option in patients with metastatic liver cancer, according to an expert.

5 Recent Cancer Drug Approvals That Patients May Have Missed

June 3rd 2021, 1:00pm

Article

The Food and Drug Administration has had a busy couple of weeks, approving several agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.

FDA Grants Approval for Truseltiq for Metastatic Cholangiocarcinoma Treatment

May 29th 2021, 1:52pm

Article

The FDA approved a kinase inhibitor for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other arrangement.

Second-Line Chemotherapy Combo Shows Survival Benefit in Patients With Advanced Liver Cancer

May 26th 2021, 9:00pm

Article

The study results, according to the authors, suggest that the combination of folinic acid plus the chemotherapies fluorouracil and oxaliplatin should become the standard-of-care therapy in patients with advanced biliary tract cancer whose disease progressed with cisplatin and gemcitabine.

Neoadjuvant Libtayo Shows Promise for Patients With Hepatocellular Carcinoma

May 10th 2021, 3:00pm

Article

Twenty percent of patients with resectable hepatocellular carcinoma had a significant amount of cell death when receiving Libtayo before surgical intervention.